These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 28597459)

  • 1. Novel (Oral) Anticoagulant Challenges in Surgery.
    Blennerhassett R; Favaloro EJ; Pasalic L
    Semin Thromb Hemost; 2017 Oct; 43(7):706-715. PubMed ID: 28597459
    [No Abstract]   [Full Text] [Related]  

  • 2. Replacing warfarin therapy with the newer direct oral anticoagulants, or simply a growth in anticoagulation therapy? Implications for pathology testing.
    Favaloro EJ; Pasalic L; Lippi G
    Pathology; 2017 Oct; 49(6):639-643. PubMed ID: 28826832
    [No Abstract]   [Full Text] [Related]  

  • 3. Using new oral anticoagulants in patients undergoing major orthopedic surgery.
    Bass AR
    Curr Rheumatol Rep; 2015 Apr; 17(4):25. PubMed ID: 25854486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Direct Oral Anticoagulants Among Patients Undergoing Cardioversion: The Importance of Timing Before Cardioversion.
    Warden BA; MacKay J; Jafari M; Willman A; Stecker EC
    J Am Heart Assoc; 2018 Nov; 7(22):e010854. PubMed ID: 30571504
    [No Abstract]   [Full Text] [Related]  

  • 5. Anticoagulants: What is new and what is the standard?
    Lesko LJ
    Clin Pharmacol Ther; 2016 Aug; 100(2):126-8. PubMed ID: 27197625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stability of direct oral anticoagulants in whole blood and plasma from patients in steady state treatment.
    McGrail R; Revsholm J; Nissen PH; Grove EL; Hvas AM
    Thromb Res; 2016 Dec; 148():107-110. PubMed ID: 27835819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Appropriateness of non-vitamin K antagonist oral anticoagulant dose in patients with atrial fibrillation in Israel: A population-based study.
    Ellis MH; Dotan SG; Hammerman A; Battat E; Derazne E; Avnery O
    Thromb Res; 2018 Sep; 169():140-142. PubMed ID: 30056294
    [No Abstract]   [Full Text] [Related]  

  • 8. Practical recommendations on incorporating new oral anticoagulants into routine practice.
    Randhawa J; Thiruchelvam N; Ghobrial M; Spiro T; Clark B; Haddad A; Daw H
    Clin Adv Hematol Oncol; 2014 Oct; 12(10):675-83. PubMed ID: 25658892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights From Practice With Use of Direct Oral Anticoagulants in Transplantation.
    Alsheikh R; Alfayez OM; Al Yami MS
    Prog Transplant; 2018 Dec; 28(4):380-385. PubMed ID: 30222041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is it reasonable to use a lower DOACs dose in some patients with VTE? Yes.
    Imberti D; Mastroiacovo D
    Intern Emerg Med; 2017 Aug; 12(5):561-563. PubMed ID: 28647891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Review on the New and Old Anticoagulants.
    Orthop Nurs; 2019; 38(1):53-54. PubMed ID: 30676578
    [No Abstract]   [Full Text] [Related]  

  • 12. Validation of an LC-MS/MS method for the simultaneous quantification of dabigatran, rivaroxaban and apixaban in human plasma.
    Baldelli S; Cattaneo D; Pignatelli P; Perrone V; Pastori D; Radice S; Violi F; Clementi E
    Bioanalysis; 2016 Feb; 8(4):275-83. PubMed ID: 26808218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perioperative complications with new oral anticoagulants dabigatran, apixaban, and rivaroxaban in Mohs micrographic surgery: A retrospective study.
    Antia C; Hone N; Gloster H
    J Am Acad Dermatol; 2017 Nov; 77(5):967-968. PubMed ID: 29029905
    [No Abstract]   [Full Text] [Related]  

  • 14. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
    Di Lullo L; Ronco C; Cozzolino M; Russo D; Russo L; Di Iorio B; De Pascalis A; Barbera V; Galliani M; Vitaliano E; Campana C; Santoboni F; Bellasi A
    Thromb Res; 2017 Jul; 155():38-47. PubMed ID: 28482261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome.
    Malec K; Góralczyk T; Undas A
    Thromb Res; 2017 Apr; 152():93-97. PubMed ID: 27989533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. National Trends in Ambulatory Oral Anticoagulant Use.
    Barnes GD; Lucas E; Alexander GC; Goldberger ZD
    Am J Med; 2015 Dec; 128(12):1300-5.e2. PubMed ID: 26144101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
    Dumont B; Faille D; Ajzenberg N
    Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dermatosurgery in the age of novel oral anticoagulants/direct oral anticoagulants].
    Löser C; Nast A; Zeymer U
    Hautarzt; 2019 Nov; 70(11):850-853. PubMed ID: 31560079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants.
    Weitz JI; Jaffer IH
    Pol Arch Med Wewn; 2016 Sep; 126(9):688-696. PubMed ID: 27592622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prescribing of NOACs has outnumbered warfarin: exploring how physicians choose anticoagulant treatments.
    Eek AK; Øie E; Granas AG
    Eur J Clin Pharmacol; 2018 Mar; 74(3):323-330. PubMed ID: 29149366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.